126 related articles for article (PubMed ID: 16343823)
1. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity.
Henderson CJ; Pass GJ; Wolf CR
Toxicol Lett; 2006 Mar; 162(1):111-7. PubMed ID: 16343823
[TBL] [Abstract][Full Text] [Related]
2. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
[TBL] [Abstract][Full Text] [Related]
3. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
4. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
[TBL] [Abstract][Full Text] [Related]
5. Hepatic cytochrome P-450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liver.
Mutch DM; Crespy V; Clough J; Henderson CJ; Lariani S; Mansourian R; Moulin J; Wolf CR; Williamson G
Am J Physiol Gastrointest Liver Physiol; 2006 Jul; 291(1):G63-72. PubMed ID: 16455785
[TBL] [Abstract][Full Text] [Related]
6. Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice.
Wang XJ; Chamberlain M; Vassieva O; Henderson CJ; Wolf CR
Biochem J; 2005 Jun; 388(Pt 3):857-67. PubMed ID: 15717863
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
Boggs JW; Hop CE; McNamara E; Deng Y; Messick K; West K; Choo EF
Mol Pharm; 2014 Mar; 11(3):1062-8. PubMed ID: 24450768
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the metabolism of midazolam in C57BL/6J and hepatic reductase null (HRN) mice.
Grimsley A; Foster A; Gallagher R; Hutchison M; Lundqvist A; Pickup K; Wilson ID; Samuelsson K
Biochem Pharmacol; 2014 Dec; 92(4):701-11. PubMed ID: 25450676
[TBL] [Abstract][Full Text] [Related]
9. The disruption of hepatic cytochrome p450 reductase alters mouse lipid metabolism.
Mutch DM; Klocke B; Morrison P; Murray CA; Henderson CJ; Seifert M; Williamson G
J Proteome Res; 2007 Oct; 6(10):3976-84. PubMed ID: 17722906
[TBL] [Abstract][Full Text] [Related]
10. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
11. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling.
Arlt VM; Poirier MC; Sykes SE; John K; Moserova M; Stiborova M; Wolf CR; Henderson CJ; Phillips DH
Toxicol Lett; 2012 Sep; 213(2):160-6. PubMed ID: 22759596
[TBL] [Abstract][Full Text] [Related]
12. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity.
Xue X; Gong L; Qi X; Wu Y; Xing G; Yao J; Luan Y; Xiao Y; Li Y; Wu X; Chen M; Gu J; Ren J
Toxicol Lett; 2011 Aug; 205(1):47-54. PubMed ID: 21596114
[TBL] [Abstract][Full Text] [Related]
13. Application of hepatic cytochrome b
Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
[TBL] [Abstract][Full Text] [Related]
14. Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene.
Wu L; Gu J; Weng Y; Kluetzman K; Swiatek P; Behr M; Zhang QY; Zhuo X; Xie Q; Ding X
Genesis; 2003 Aug; 36(4):177-81. PubMed ID: 12929087
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase.
Henderson CJ; Otto DM; Carrie D; Magnuson MA; McLaren AW; Rosewell I; Wolf CR
J Biol Chem; 2003 Apr; 278(15):13480-6. PubMed ID: 12566435
[TBL] [Abstract][Full Text] [Related]
16. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
[TBL] [Abstract][Full Text] [Related]
17. Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system.
Finn RD; McLaren AW; Carrie D; Henderson CJ; Wolf CR
J Pharmacol Exp Ther; 2007 Jul; 322(1):40-7. PubMed ID: 17435107
[TBL] [Abstract][Full Text] [Related]
18. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
[TBL] [Abstract][Full Text] [Related]
19. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome b
Reed L; Mrizova I; Barta F; Indra R; Moserova M; Kopka K; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
Arch Toxicol; 2018 Apr; 92(4):1625-1638. PubMed ID: 29368147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
